Transfusion of phosphoenolpyruvate-treated blood increases oxygen consumption in acute hemorrhage.
BACKGROUND
Incubating blood with phosphoenolpyruvate decreases hemoglobin oxygen affinity (HOA). This study compared transfusion with phosphoenolpyruvate-treated blood and conventionally stored blood on oxygen consumption in acutely anemic dogs.


METHODS
Dogs underwent isovolemic hemodilution (hematocrit = 10%). After 1 hour they were transfused to a hematocrit of 18% with control or phosphoenolpyruvate treated blood. Cardiac output, co-oxymetry, and hemoglobin P50 measurements allowed calculation of oxygen consumption during anemia, and posttransfusion.


RESULTS
Hemodilution doubled cardiac output. Transfusion with phosphoenolpyruvate-treated blood allowed greater O2 consumption than control (8.31+/-2.1 and 3.73+/-0.11 cc/kg/mm). There were no differences in arterial or venous PO2 or pH; there were marked differences in HOA, measured by posttransfusion P50 (21+/-3 versus 47+/-4), and mixed venous O2 saturation.


CONCLUSIONS
Decreased HOA results in increased O2 consumption in dogs subjected to anemic hypoxia. Phosphoenolpyruvate-treated blood provides increased oxygen consumption at a similar hematocrit when compared with untreated banked blood.
Cornum
R L
RL
Urology and General Surgery, Brooke Army Medical Center, Fort Sam Houston, Texas 78234-6345, USA.
Martin
R R
RR
Bandy
W C
WC
D000208:Acute Disease; D000818:Animals; D001793:Blood Preservation; D001803:Blood Transfusion; D002302:Cardiac Output; D004285:Dogs; D004912:Erythrocytes / Q000187:drug effects*; D006400:Hematocrit; D006438:Hemodilution; D006439:Hemodynamics; D006454:Hemoglobins / Q000032:analysis; D006470:Hemorrhage / Q000097:blood / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption; D010108:Oxyhemoglobins / Q000032:analysis; D010728:Phosphoenolpyruvate / Q000494:pharmacology*
D006454:Hemoglobins; D010108:Oxyhemoglobins; D010728:Phosphoenolpyruvate; D010100:Oxygen